Pancreatic Cancer Research

ResearcherNational Cancer Center HospitalActive in the last 2 years

Yoji Kishi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8885-1210; OpenAlex author ID A5078172686. Sources: OpenAlex.

Their work

Papers
25 (first author 5, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 8 papers · 2026: 3 papers

Papers 25

  1. Radiologic-pathologic discrepancy in the tumor size assessment of pancreatic ductal adenocarcinoma in the era of preoperative therapy. Last author DOI 10.1007/s00595-026-03419-5↗
  2. Pancreatic cancer mimicking ectopic pancreas origin: a rare case after neonatal pyloromyotomy. Last author DOI 10.1007/s12328-026-02352-x↗
  3. Clinical benefit of locoregional therapy for oligometastasis after surgery for pancreatic cancer: a single center retrospective study. Last author DOI 10.1186/s12885-026-16566-2↗
  4. Risk of hepatic steatosis with the preoperative treatment of pancreatic cancer and the short-term postoperative outcomes. First author DOI 10.1007/s00595-024-02895-x↗
  5. Prognostic impact of dose reduced S-1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study. Last author DOI 10.1007/s10147-025-02742-0↗
  6. Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe carbohydrate restriction: ketogenic diet. Last author DOI 10.1007/s12328-025-02221-z↗
  7. A novel scoring system for prognostic stratification of node-positive pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.gassur.2025.102187↗
  8. Surgery based on resectability status of pancreatic cancer: a narrative review. Last author DOI 10.1093/jjco/hyaf131↗
  9. Dissecting Tumor Size Underestimation in Pancreatic Cancer: A Comparative Analysis of Preoperative Treatments. First author DOI 10.1245/s10434-025-16917-6↗
  10. ASO Author Reflections: Reshaping Tumor Size through Insights from Pancreatic Cancer Imaging and Pathology. First author DOI 10.1245/s10434-025-16983-w↗
  11. Reply to: Letter to the Editor of Annals of Surgical Oncology Concerning "Dissecting Tumor Size Underestimation in Pancreatic Cancer: A Comparative Analysis of… First author DOI 10.1245/s10434-025-17816-6↗
  12. A case of superior mesenteric artery stenting for small intestinal ischaemia caused by superior mesenteric artery invasion of pancreatic cancer. Co-author DOI 10.1093/bjrcr/uaae031↗
  13. Preoperative CA19‑9 level and dual time point FDG‑PET/CT as strong biological indicators of borderline resectability in pancreatic cancer: A retrospective stud… Last author DOI 10.3892/ol.2024.14412↗
  14. Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report. Last author DOI 10.3892/ol.2024.14503↗
  15. ASO Author Reflections: Proposal of Tumor Size as an Index for Biologic Factor of Resectability Status of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-023-14261-1↗
  16. Let's come together to fight with pancreatic cancer. Co-author DOI 10.21037/cco-23-7↗
  17. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Last author DOI 10.3390/cancers15041101↗
  18. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Co-author DOI 10.1038/s41416-021-01639-9↗
  19. Preoperative Rapid Weight Loss as a Prognostic Predictor After Surgical Resection for Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002186↗
  20. Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study. Last author DOI 10.1186/s12885-022-10116-2↗
  21. Clinical Impact of Dual Time Point 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer. Last author DOI 10.3390/cancers14153688↗
  22. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  23. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/bjs5.50130↗
  24. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗
  25. Total pancreatectomy with en bloc celiac axis resection for a pancreatic adenocarcinoma involving both the gastroduodenal artery and the celiac artery. Co-author DOI 10.5754/hge11687↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takahiro Einama · 16 shared papers, 2022–2026 · strength 3.59
  2. Hideki Ueno · 13 shared papers, 2022–2026 · strength 2.96
  3. Kazuki Kobayashi · 9 shared papers, 2024–2025 · strength 2.67
  4. Kazuki Kobayashi · 5 shared papers, 2022–2026 · strength 1.02
  5. Yoichi Miyata · 3 shared papers, 2023–2025 · strength 0.87
  6. Mayuko Ohara · 3 shared papers, 2024–2026 · strength 0.72
  7. Koki Ichio · 3 shared papers, 2024–2026 · strength 0.72
  8. Yoshifumi Beck · 2 shared papers, 2025 · strength 0.49
  9. Kazuaki Shimada · 5 shared papers, 2012–2022 · strength 0.45
  10. Satoshi Nara · 5 shared papers, 2012–2022 · strength 0.45
  11. Minoru Esaki · 5 shared papers, 2012–2022 · strength 0.45
  12. Nobuyoshi Hiraoka · 4 shared papers, 2016–2022 · strength 0.42
  13. Makoto Nishikawa · 2 shared papers, 2022–2025 · strength 0.37
  14. Yoshinori Ino · 3 shared papers, 2016–2022 · strength 0.29
  15. Yuta Hasegawa · 1 shared paper, 2026 · strength 0.29
  16. Hiroshi Shinmoto · 1 shared paper, 2024 · strength 0.26
  17. Hiroshi Kuwamura · 1 shared paper, 2024 · strength 0.26
  18. Akifumi Kimura · 1 shared paper, 2025 · strength 0.22
  19. Mayumi Hoshikawa · 1 shared paper, 2022 · strength 0.16
  20. Junji Yamamoto · 1 shared paper, 2022 · strength 0.16
  21. Shutaro Hori · 2 shared papers, 2016–2020 · strength 0.15
  22. Noriteru Doi · 1 shared paper, 2022 · strength 0.14
  23. Utako Ishimoto · 1 shared paper, 2022 · strength 0.14
  24. Kosei Nakajima · 1 shared paper, 2022 · strength 0.14
  25. Yuji Heike · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.